Jihye Park1,2, Brenna E Blackburn1,2, Patricia A Ganz3, Kerry Rowe4, John Snyder4, Yuan Wan5, Vikrant Deshmukh6, Michael Newman1,6, Alison Fraser5, Ken Smith5, Kim Herget7, Anne C Kirchhoff1,8, Dev Abraham1,9, Jaewhan Kim10, Marcus Monroe1,11, Mia Hashibe1,2. 1. Huntsman Cancer Institute, Salt Lake City, Utah. 2. Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah. 3. Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, California. 4. Intermountain Healthcare, Salt Lake City, Utah. 5. Pedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, Utah. 6. University of Utah Health Sciences Center, Salt Lake City, Utah. 7. Utah Cancer Registry, University of Utah, Salt Lake City, Utah. 8. Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah. 9. Division of Endocrinology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah. 10. College of Health, University of Utah, Salt Lake City, Utah. 11. Division of Otolaryngology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah.
Abstract
Context: Thyroid cancer survivors are at high risk of developing multiple cardiac and vascular conditions as consequence of cancer diagnosis and treatment. However, it is still unclear how the baseline and prognostic factors, as well as cancer treatments, play a role in increasing cardiac and vascular disease risk among thyroid cancer survivors. Objective: To investigate the association between potential risk factors, treatment effects, and cardiovascular disease (CVD) outcomes in thyroid cancer survivors. Design, Setting, Patients: Primary thyroid cancer survivors, diagnosed from 1997 to 2012 (n = 3822), were identified using the statewide Utah Population Database. The medical records were used to ascertain information on risk factors and CVD outcomes. Cox proportional hazards models were used to assess the risk of CVD with baseline demographic data and clinical factors. Results: Among thyroid cancer survivors, age and year at cancer diagnosis, cancer stage, sex, baseline body mass index, baseline comorbidities, and TSH suppression therapy were significantly associated with CVD risk 1 to 5 years after cancer diagnosis. Patients who were male, overweight or obese, older at cancer diagnosis, and diagnosed with cancer since 2005 had an increased risk of CVD compared with patients who were female, had a normal body mass index, were younger at cancer diagnosis, and diagnosed with cancer from 1997 to 1999. Administration of TSH suppression therapy, distant metastases at cancer diagnosis, and a higher Charlson comorbidity index score were associated with an increased CVD risk among thyroid cancer survivors. Conclusions: Our findings suggest that examining the effect of thyroid cancer diagnosis, cancer treatment, and demographic characteristics on the risk of CVD is critical.
Context:Thyroid cancer survivors are at high risk of developing multiple cardiac and vascular conditions as consequence of cancer diagnosis and treatment. However, it is still unclear how the baseline and prognostic factors, as well as cancer treatments, play a role in increasing cardiac and vascular disease risk among thyroid cancer survivors. Objective: To investigate the association between potential risk factors, treatment effects, and cardiovascular disease (CVD) outcomes in thyroid cancer survivors. Design, Setting, Patients: Primary thyroid cancer survivors, diagnosed from 1997 to 2012 (n = 3822), were identified using the statewide Utah Population Database. The medical records were used to ascertain information on risk factors and CVD outcomes. Cox proportional hazards models were used to assess the risk of CVD with baseline demographic data and clinical factors. Results: Among thyroid cancer survivors, age and year at cancer diagnosis, cancer stage, sex, baseline body mass index, baseline comorbidities, and TSH suppression therapy were significantly associated with CVD risk 1 to 5 years after cancer diagnosis. Patients who were male, overweight or obese, older at cancer diagnosis, and diagnosed with cancer since 2005 had an increased risk of CVD compared with patients who were female, had a normal body mass index, were younger at cancer diagnosis, and diagnosed with cancer from 1997 to 1999. Administration of TSH suppression therapy, distant metastases at cancer diagnosis, and a higher Charlson comorbidity index score were associated with an increased CVD risk among thyroid cancer survivors. Conclusions: Our findings suggest that examining the effect of thyroid cancer diagnosis, cancer treatment, and demographic characteristics on the risk of CVD is critical.
Authors: Robert W Flynn; Sandra R Bonellie; Roland T Jung; Thomas M MacDonald; Andrew D Morris; Graham P Leese Journal: J Clin Endocrinol Metab Date: 2009-11-11 Impact factor: 5.958
Authors: Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-06-02 Impact factor: 508.702
Authors: Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice Journal: Health Phys Date: 2014-02 Impact factor: 1.316
Authors: So Young Kim; Dae Myoung Yoo; Mi Jung Kwon; Ji Hee Kim; Joo-Hee Kim; Woo Jin Bang; Sung Kyun Kim; Hyo Geun Choi Journal: J Pers Med Date: 2022-05-27
Authors: Maria Papaleontiou; Debbie W Chen; Mousumi Banerjee; David Reyes-Gastelum; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: Thyroid Date: 2021-04-23 Impact factor: 6.506
Authors: Thomas J Semrad; Qian Li; Melanie Goldfarb; Alison Semrad; Michael Campbell; D Gregory Farwell; Theresa H M Keegan Journal: J Adolesc Young Adult Oncol Date: 2021-01-28 Impact factor: 1.757